GeneDx (WGS) Stock Forecast, Price Target & Predictions
WGS Stock Forecast
GeneDx stock forecast is as follows: an average price target of $35.75 (represents a -5.60% downside from WGS’s last price of $37.87) and a rating consensus of 'Buy', based on 4 wall street analysts offering a 1-year stock forecast.
WGS Price Target
The average price target for GeneDx (WGS) is $35.75 based on 1-year price targets from 4 Wall Street analysts in the past 3 months, with a price target range of $45.00 to $21.00. This represents a potential -5.60% downside from WGS's last price of $37.87.
WGS Analyst Ratings
According to 4 Wall Street analysts, GeneDx's rating consensus is 'Buy'. The analyst rating breakdown for WGS stock is 0 'Strong Buy' (0.00%), 3 'Buy' (75.00%), 1 'Hold' (25.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
GeneDx Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Aug 27, 2024 | Brandon Couillard | Wells Fargo | $34.00 | $35.35 | -3.82% | -10.22% |
| Jul 31, 2024 | Mark Massaro | BTIG | $45.00 | $30.13 | 49.35% | 18.83% |
| Jul 10, 2024 | Bill Bonello | Craig-Hallum | $43.00 | $29.81 | 44.25% | 13.55% |
| Jun 26, 2024 | Mark Massaro | BTIG | $35.00 | $26.19 | 33.64% | -7.58% |
| Jun 03, 2024 | Tycho Peterson | Jefferies | $21.00 | $19.61 | 7.09% | -44.55% |
| Apr 30, 2024 | Mark Massaro | BTIG | $19.00 | $11.00 | 72.73% | -49.83% |
The latest GeneDx stock forecast, released on Aug 27, 2024 by Brandon Couillard from Wells Fargo, set a price target of $34.00, which represents a -3.82% decrease from the stock price at the time of the forecast ($35.35), and a -10.22% decrease from WGS last price ($37.87).
GeneDx Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 1 | 4 | 6 |
| Avg Price Target | $34.00 | $39.25 | $32.83 |
| Last Closing Price | $37.87 | $37.87 | $37.87 |
| Upside/Downside | -10.22% | 3.64% | -13.31% |
In the current month, the average price target of GeneDx stock is $34.00, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a -10.22% decrease as opposed to GeneDx's last price of $37.87. This month's average price target is down -13.38% compared to last quarter, and up 3.56% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 27, 2024 | Wells Fargo | - | Equal-Weight | Initialise |
| Jul 31, 2024 | Craig-Hallum | Buy | Buy | Hold |
| Jul 31, 2024 | Cowen & Co. | Buy | Buy | Hold |
| Jul 31, 2024 | BTIG | Buy | Buy | Hold |
| Jul 10, 2024 | Craig-Hallum | - | Buy | Initialise |
| Jun 26, 2024 | BTIG | Buy | Buy | Hold |
| Apr 30, 2024 | Cowen & Co. | Buy | Buy | Hold |
| Apr 30, 2024 | BTIG | Buy | Buy | Hold |
GeneDx's last stock rating was published by Wells Fargo on Aug 27, 2024. The company Initialise its WGS rating from "null" to "Equal-Weight".
GeneDx Financial Forecast
GeneDx Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $43.14M | $61.35M | $83.23M | $36.17M | $53.94M | $57.80M | $43.18M |
| Avg Forecast | $84.26M | $82.05M | $90.45M | $73.26M | $79.68M | $76.63M | $75.11M | $69.56M | $67.14M | $64.98M | $59.31M | $49.45M | $54.24M | $52.42M | $47.59M | $40.14M | $70.96M | $67.74M | $67.55M | $47.50M | $49.67M | $42.67M |
| High Forecast | $85.78M | $83.53M | $92.08M | $74.58M | $81.12M | $78.01M | $76.46M | $70.82M | $68.35M | $66.15M | $60.38M | $50.34M | $55.22M | $55.41M | $48.44M | $40.87M | $72.24M | $68.96M | $68.25M | $47.99M | $50.18M | $43.11M |
| Low Forecast | $82.46M | $80.30M | $88.52M | $71.69M | $77.98M | $74.99M | $73.50M | $68.08M | $65.70M | $63.59M | $58.04M | $48.40M | $53.08M | $48.01M | $46.57M | $39.29M | $69.44M | $66.29M | $66.92M | $47.05M | $49.20M | $42.27M |
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | - | 1 | 4 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.07% | 0.86% | 1.23% | 0.54% | 1.14% | 1.16% | 1.01% |
GeneDx's average Quarter revenue forecast for Jun 23 based on 2 analysts is $47.59M, with a low forecast of $46.57M, and a high forecast of $48.44M. WGS's average Quarter revenue forecast represents a 10.31% increase compared to the company's last Quarter revenue of $43.14M (Mar 23).
GeneDx EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | - | 1 | 4 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $-46.16M | $-79.56M | $-79.32M | $-153.25M | $-83.47M | $-33.92M | $37.57M |
| Avg Forecast | $-63.12M | $-61.47M | $-67.76M | $-54.88M | $-59.70M | $-57.41M | $-56.27M | $-52.11M | $-50.30M | $-48.68M | $-44.43M | $-37.05M | $-40.64M | $-39.27M | $-35.65M | $-30.07M | $-53.16M | $-50.75M | $-50.61M | $-35.59M | $-37.21M | $-31.97M |
| High Forecast | $-61.77M | $-60.15M | $-66.31M | $-53.71M | $-58.42M | $-56.18M | $-55.06M | $-51.00M | $-49.22M | $-47.64M | $-43.48M | $-36.26M | $-39.77M | $-35.96M | $-34.89M | $-29.43M | $-52.03M | $-49.66M | $-50.13M | $-35.25M | $-36.86M | $-31.67M |
| Low Forecast | $-64.26M | $-62.58M | $-68.98M | $-55.87M | $-60.77M | $-58.44M | $-57.28M | $-53.05M | $-51.20M | $-49.56M | $-45.23M | $-37.72M | $-41.37M | $-41.51M | $-36.29M | $-30.62M | $-54.12M | $-51.66M | $-51.13M | $-35.95M | $-37.59M | $-32.30M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.53% | 1.50% | 1.56% | 3.03% | 2.35% | 0.91% | -1.18% |
2 analysts predict WGS's average Quarter EBITDA for Dec 21 to be $-37.21M, with a high of $-36.86M and a low of $-37.59M. This is -199.05% lower than GeneDx's previous annual EBITDA (Sep 21) of $37.57M.
GeneDx Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | - | 1 | 4 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $-60.99M | $-308.76M | $-77.58M | $-85.74M | $-64.49M | $-41.13M | $31.39M |
| Avg Forecast | - | - | - | - | $2.33M | $199.63K | $-1.33M | $-3.57M | $-5.48M | $-6.92M | $-9.52M | $-17.75M | $-17.39M | $-34.87M | $-34.96M | $-41.88M | $-161.95M | $-181.53M | $-180.07M | $-281.09M | $-226.24M | $-163.97M |
| High Forecast | - | - | - | - | $2.38M | $204.31K | $-1.29M | $-3.47M | $-5.33M | $-6.73M | $-9.25M | $-17.25M | $-16.91M | $-31.41M | $-33.99M | $-40.72M | $-157.45M | $-176.49M | $-177.87M | $-277.65M | $-223.48M | $-161.96M |
| Low Forecast | - | - | - | - | $2.26M | $194.08K | $-1.36M | $-3.65M | $-5.61M | $-7.08M | $-9.74M | $-18.16M | $-17.80M | $-38.86M | $-35.78M | $-42.86M | $-165.74M | $-185.78M | $-182.49M | $-284.86M | $-229.28M | $-166.17M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.46% | 1.91% | 0.43% | 0.48% | 0.23% | 0.18% | -0.19% |
GeneDx's average Quarter net income forecast for Dec 21 is $-226.24M, with a range of $-229.28M to $-223.48M. WGS's average Quarter net income forecast represents a -820.71% decrease compared to the company's last Quarter net income of $31.39M (Sep 21).
GeneDx SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | - | 1 | 4 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $57.14M | $72.44M | $89.31M | $104.15M | $72.33M | $100.85M | $55.35M |
| Avg Forecast | $84.69M | $82.47M | $90.91M | $73.63M | $80.09M | $77.02M | $75.49M | $69.92M | $67.48M | $65.31M | $59.61M | $49.70M | $54.52M | $52.68M | $47.83M | $40.35M | $71.32M | $68.08M | $67.89M | $47.74M | $49.92M | $42.89M |
| High Forecast | $86.21M | $83.95M | $92.54M | $74.96M | $81.53M | $78.41M | $76.85M | $71.17M | $68.69M | $66.49M | $60.68M | $50.60M | $55.50M | $55.69M | $48.69M | $41.07M | $72.61M | $69.31M | $68.60M | $48.23M | $50.44M | $43.33M |
| Low Forecast | $82.88M | $80.70M | $88.96M | $72.06M | $78.37M | $75.37M | $73.87M | $68.42M | $66.04M | $63.91M | $58.34M | $48.64M | $53.35M | $48.25M | $46.80M | $39.48M | $69.80M | $66.63M | $67.26M | $47.29M | $49.45M | $42.48M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.42% | 1.02% | 1.31% | 1.53% | 1.52% | 2.02% | 1.29% |
GeneDx's average Quarter SG&A projection for Jun 23 is $47.83M, based on 2 Wall Street analysts, with a range of $46.80M to $48.69M. The forecast indicates a -16.30% fall compared to WGS last annual SG&A of $57.14M (Mar 23).
GeneDx EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | - | 1 | 4 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $-3.04 | $-2.86 | $-0.20 | $-0.25 | $-0.26 | $-0.17 | $0.17 |
| Avg Forecast | - | - | - | - | $0.09 | $0.01 | $-0.05 | $-0.13 | $-0.21 | $-0.26 | $-0.36 | $-0.67 | $-0.65 | $-1.31 | $-1.31 | $-1.57 | $-6.08 | $-6.82 | $-6.76 | $-10.56 | $-8.50 | $-6.16 |
| High Forecast | - | - | - | - | $0.09 | $0.01 | $-0.05 | $-0.13 | $-0.20 | $-0.25 | $-0.35 | $-0.65 | $-0.64 | $-1.18 | $-1.28 | $-1.53 | $-5.92 | $-6.63 | $-6.68 | $-10.43 | $-8.40 | $-6.08 |
| Low Forecast | - | - | - | - | $0.09 | $0.01 | $-0.05 | $-0.14 | $-0.21 | $-0.27 | $-0.37 | $-0.68 | $-0.67 | $-1.46 | $-1.34 | $-1.61 | $-6.23 | $-6.98 | $-6.86 | $-10.70 | $-8.61 | $-6.24 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.93% | 0.47% | 0.03% | 0.04% | 0.02% | 0.02% | -0.03% |
According to 2 Wall Street analysts, GeneDx's projected average Quarter EPS for Dec 21 is $-8.50, with a low estimate of $-8.61 and a high estimate of $-8.40. This represents a -5099.82% decrease compared to WGS previous annual EPS of $0.17 (Sep 21).
GeneDx Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| BBLN | Babylon | $0.55 | $5.50 | 900.00% | Buy |
| AKLI | Akili | $0.43 | $3.25 | 655.81% | Buy |
| HCTI | Healthcare Triangle | $0.33 | $2.00 | 506.06% | Buy |
| DH | Definitive Healthcare | $4.44 | $9.92 | 123.42% | Hold |
| CERT | Certara | $10.95 | $21.75 | 98.63% | Hold |
| PRVA | Privia Health Group | $18.95 | $33.82 | 78.47% | Buy |
| WGS | GeneDx | $37.87 | $35.75 | -5.60% | Buy |
WGS Forecast FAQ
Is GeneDx a good buy?
Yes, according to 4 Wall Street analysts, GeneDx (WGS) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 3 'Buy' recommendations, accounting for 75.00% of WGS's total ratings.
What is WGS's price target?
GeneDx (WGS) average price target is $35.75 with a range of $21 to $45, implying a -5.60% from its last price of $37.87. The data is based on 4 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will GeneDx stock go up soon?
According to Wall Street analysts' prediction for WGS stock, the company can go down by -5.60% (from the last price of $37.87 to the average price target of $35.75), up by 18.83% based on the highest stock price target, and down by -44.55% based on the lowest stock price target.
Can GeneDx stock reach $60?
WGS's average twelve months analyst stock price target of $35.75 does not support the claim that GeneDx can reach $60 in the near future.
What is GeneDx's current price target trend?
1 Wall Street analyst forecast a $34 price target for GeneDx (WGS) this month, down -10.22% from its last price of $37.87. Compared to the last 3 and 12 months, the average price target increased by 3.64% and decreased by -13.31%, respectively.
What are GeneDx's analysts' financial forecasts?
GeneDx's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $300.99M (high $306.41M, low $294.55M), average EBITDA is $-225M (high $-221M, low $-230M), average net income is $-2.369M (high $-2.174M, low $-2.554M), average SG&A $302.51M (high $307.96M, low $296.04M), and average EPS is $-0.089 (high $-0.0817, low $-0.096). WGS's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $330.02M (high $335.96M, low $322.96M), average EBITDA is $-247M (high $-242M, low $-252M), average net income is $0 (high $0, low $0), average SG&A $331.69M (high $337.66M, low $324.6M), and average EPS is $0 (high $0, low $0).
Did the WGS's actual financial results beat the analysts' financial forecasts?
Based on GeneDx's last annual report (Dec 2022), the company's revenue was $234.69M, which missed the average analysts forecast of $253.76M by -7.51%. Apple's EBITDA was $-396M, beating the average prediction of $-190M by 108.10%. The company's net income was $-549M, missing the average estimation of $-805M by -31.77%. Apple's SG&A was $338.24M, beating the average forecast of $255.04M by 32.62%. Lastly, the company's EPS was $-5.08, missing the average prediction of $-30.229 by -83.20%. In terms of the last quarterly report (Mar 2023), GeneDx's revenue was $43.14M, beating the average analysts' forecast of $40.14M by 7.46%. The company's EBITDA was $-46.16M, beating the average prediction of $-30.074M by 53.49%. GeneDx's net income was $-60.989M, beating the average estimation of $-41.883M by 45.62%. The company's SG&A was $57.14M, beating the average forecast of $40.35M by 41.62%. Lastly, the company's EPS was $-3.04, beating the average prediction of $-1.573 by 93.20%